These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 11410071

  • 1. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L, Uzick M.
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG, Zacho J.
    Nutr Metab Cardiovasc Dis; 2009 Oct 16; 19(8):521-4. PubMed ID: 19695857
    [Abstract] [Full Text] [Related]

  • 4. A "natural" remedy for high cholesterol.
    Johns Hopkins Med Lett Health After 50; 1999 Jul 16; 11(5):3. PubMed ID: 10377908
    [No Abstract] [Full Text] [Related]

  • 5. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS, Larsen AI.
    Tidsskr Nor Laegeforen; 2009 Jun 11; 129(12):1221-4. PubMed ID: 19521445
    [Abstract] [Full Text] [Related]

  • 6. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W, Köenig W.
    J Cardiovasc Risk; 2003 Jun 11; 10(3):169-79. PubMed ID: 12775949
    [Abstract] [Full Text] [Related]

  • 7. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004 Jun 11; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W.
    Int J Cardiol; 2005 Feb 15; 98(2):199-206. PubMed ID: 15686768
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R.
    Ther Adv Cardiovasc Dis; 2009 Aug 15; 3(4):309-15. PubMed ID: 19460829
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A, Limmert T, Hoffmann U.
    Int Angiol; 2003 Mar 15; 22(1):15-23. PubMed ID: 12771851
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
    Dummer CD, Thome' FS, Zingano B, Lindoso A, Veronese FV.
    J Nephrol; 2008 Mar 15; 21(6):900-8. PubMed ID: 19034875
    [Abstract] [Full Text] [Related]

  • 16. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB.
    J Am Osteopath Assoc; 2010 Apr 15; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [Abstract] [Full Text] [Related]

  • 17. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 15; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 18. [Inflammatory markers and cytokines in cardiovascular disease].
    Ogiwara F, Takahashi M, Ikeda U.
    Rinsho Byori; 2004 Aug 15; 52(8):686-92. PubMed ID: 15478624
    [Abstract] [Full Text] [Related]

  • 19. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ, Watson KE, Weiss RE, Fonarow GC.
    Heart Dis; 2003 Aug 15; 5(1):2-7. PubMed ID: 12549983
    [Abstract] [Full Text] [Related]

  • 20. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C.
    Atheroscler Suppl; 2006 Apr 15; 7(1):21-9. PubMed ID: 16504600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.